FDA Advisory Panel Splits on Pediatric Labeling for Opioid Patch

Drug Industry Daily
A A
Two FDA advisory committees grappled with the proposed addition of information from a pediatric study to labels for Purdue Pharma’s opioid patch Butrans (buprenorphine), without coming to a clear consensus.

To View This Article:

Login

Subscribe To Drug Industry Daily